Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective,
multi-center, phase II study for 55 patients with advanced (recurrent, refractory or
metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of
the combination therapy of olaparib tablets and durvalumab IV.
Phase:
Phase 2
Details
Lead Sponsor:
Leiden University Medical Center
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Amsterdam University Medical Center AstraZeneca Erasmus Medical Center Maastricht University Medical Center Radboud University The Netherlands Cancer Institute UMC Utrecht University Medical Center Groningen